12/8/2022
In response to the unprecedented public health crisis caused by COVID-19, the federal government spent billions of dollars on developing new vaccines and treatments, to swift success: Less than a year after the pandemic was declared, medical workers got their first vaccines.
But as many people have refused the shots and stopped wearing masks, the virus still rages and mutates. In 2022 alone, 250,000 Americans have died from COVID-19, more than from strokes or diabetes.
But soon the Department of Health and Human Services will stop supplying COVID-19 treatments, and pharmacies will purchase and bill for them the same way they do for antibiotic pills or asthma inhalers. Paxlovid is expected to hit the private market in mid-2023, according to HHS plans shared in an October meeting with state health officials and clinicians.
Merck’s Lagevrio, a less-effective COVID-19 treatment pill, and AstraZeneca’s Evusheld, a preventive therapy for the immunocompromised, are on track to be commercialized sooner, sometime in the winter.
Full Link ( Msn ) Here
© CopyRights RawNews1st
